ADC Therapeutics' Licensing Partner Tanabe Pharma Files Japanese Marketing Authorization Application For ZYLONTA For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
In addition, Tanabe Pharma has entered into an exclusive sublicensing agreement with Nippon Shinyaku Co., Ltd., for the commercialization of ZYNLONTA in Japan.Recently, encouraging results from the Phase 1/2
Share
Why It Matters
A partner company asked Japan to approve ADC's cancer medicine. This is a positive step toward selling the drug in Japan.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.